Flu Vaccine Approved

Article

The vaccine approved by the FDA for the upcoming flu season contains the same three virus strains as last year.

The FDA announced last week that it had approved the formulation of the 2011-2012 influenza vaccine for the six manufacturers that are licensed to produce and distribute it in the US.

Each year, the vaccine contains the three virus strains determined to be those likely to cause the most illness during the upcoming flu season. This year’s vaccine includes the same three strains as last year’s, though those who received the vaccine last year should not be tempted to skip this year’s.

“It is important to get vaccinated every year, even if the strains in the vaccine do not change, because the protection received the previous year will diminish over time and may be too low to provide protection into the next year,” said Karen Midthun, MD, director of FDA’s Center for Biologics Evaluation and Research, in a press release.

The brand names and manufacturers of vaccine for the upcoming flu season are: Afluria (CSL Limited); Fluarix (GlaxoSmithKline Biologicals); FluLaval (ID Biomedical Corporation); FluMist (MedImmune Vaccines Inc.); Fluvirin (Novartis Vaccines and Diagnostics Limited); and Fluzone, Fluzone High-Dose, and Fluzone Intradermal (Sanofi Pasteur Inc.). (Fluzone Intradermal is delivered via a very small needle into the skin rather than muscle and is available for those aged 18 to 64.)

Around the Web

FDA approves vaccines for the 2011-2012 influenza season [FDA]

Related Videos
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
Solutions to Prevent Climate Change-Related Illness, with Janelle Bludhorn, PA-C
Kyle Fortman, PA-C, MBA: Troponin and Heart Injury Risk Screening Recommendations
What Should the American Academy of Physician Associates Focus on in 2025?
The Rising Rate of Heat-Related Illness, with Janelle Bludhorn, PA-C
Ankeet Bhatt, MD, MBA | Credit: X.com
Nanette B. Silverberg, MD: Uncovering Molluscum Epidemiology
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
A Year of RSV Highs and Lows, with Tina Tan, MD
Ryan A. Smith, MD: RSV Risk in Patients with IBD
© 2024 MJH Life Sciences

All rights reserved.